Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
The safety profile of BI 894999 was consistent with those of other BET inhibitors. Due to minimal efficacy results, further evaluation of BI 894999 as monotherapy is not planned.
Authors
- Dale R. Shepard (ORCID: https://orcid.org/0000-0003-4310-6019)
- Ahmad Awada (ORCID: https://orcid.org/0000-0001-7412-9163)
- Kristell Marzin
- Ulrich M. Lauer (ORCID: https://orcid.org/0000-0002-4557-7730)
- Lara Iglesias Docampo
- S. Postel-Vinay
- Patrick Schöffski (ORCID: https://orcid.org/0000-0001-5980-030X)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Catherine Thiéblemont (ORCID: https://orcid.org/0000-0002-9941-2448)
- Sylvie Rottey (ORCID: https://orcid.org/0000-0003-2060-3725)
- Geoffrey Ira Shapiro (ORCID: https://orcid.org/0000-0002-3331-4095)
- Rachel Galot (ORCID: https://orcid.org/0000-0002-0596-4752)
- H. Musa (ORCID: https://orcid.org/0009-0001-1222-8745)
- Behbood Sadrolhefazi
- P. Paik
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Ghent University Hospital (BE)
- Institut Jules Bordet (BE)
- Dana-Farber Cancer Institute (US)
- Boehringer Ingelheim (United States) (US)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104499
- Citations
- 6
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 4.84
Funders
- Boehringer Ingelheim